TY - JOUR
T1 - The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
AU - Solèr, M.
AU - Matz, J.
AU - Townley, R.
AU - Buhl, R.
AU - O'Brien, J.
AU - Fox, H.
AU - Thirlwell, J.
AU - Gupta, N.
AU - Della Cioppa, G.
PY - 2001
Y1 - 2001
N2 - The clinical benefit and steroid-sparing effect of treatment with the anti-immunoglobulin-E (IgE) antibody, omalizumab, was assessed in patients with moderate-to-severe allergic asthma. After a run-in period, 546 allergic asthmatics (aged 12-76 yrs), symptomatic despite inhaled corticosteroids (500-1,200 μg daily of beclomethasone dipropionate), were randomized to receive double-blind either placebo or omalizumab every 2 or 4 weeks (depending on body weight and serum total IgE) subcutaneously for 7 months. A constant beclomethasone dose was maintained during a 16-week stable-steroid phase and progressively reduced to the lowest dose required for asthma control over the following 8 weeks. The latter dose was maintained for the next 4 weeks. Asthma exacerbations represented the primary variable. Compared to the placebo group, the omalizumab group showed 58% fewer exacerbations per patient during the stable-steroid phase (p
AB - The clinical benefit and steroid-sparing effect of treatment with the anti-immunoglobulin-E (IgE) antibody, omalizumab, was assessed in patients with moderate-to-severe allergic asthma. After a run-in period, 546 allergic asthmatics (aged 12-76 yrs), symptomatic despite inhaled corticosteroids (500-1,200 μg daily of beclomethasone dipropionate), were randomized to receive double-blind either placebo or omalizumab every 2 or 4 weeks (depending on body weight and serum total IgE) subcutaneously for 7 months. A constant beclomethasone dose was maintained during a 16-week stable-steroid phase and progressively reduced to the lowest dose required for asthma control over the following 8 weeks. The latter dose was maintained for the next 4 weeks. Asthma exacerbations represented the primary variable. Compared to the placebo group, the omalizumab group showed 58% fewer exacerbations per patient during the stable-steroid phase (p
UR - http://www.scopus.com/inward/record.url?scp=0034881877&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034881877&partnerID=8YFLogxK
U2 - 10.1183/09031936.01.00092101
DO - 10.1183/09031936.01.00092101
M3 - Article
C2 - 11529281
AN - SCOPUS:0034881877
VL - 18
SP - 254
EP - 261
JO - Scandinavian Journal of Respiratory Diseases
JF - Scandinavian Journal of Respiratory Diseases
SN - 0903-1936
IS - 2
ER -